ORA TUTT IN GINOCCHIO AHAHHA chi era dentro guadagna come un maiale chi e
fuori guarda SGRAT SGRAT

"@ SYBER_GURU @" <xxxi@virgilio.it> ha scritto nel messaggio
news:4371fb40$0$27598$4fafbaef@reader1.news.tin.it ...
> ORA TUTT IN GINOCCHIO AHAHHA chi era dentro guadagna come un maiale chi e
> fuori guarda SGRAT SGRAT



Questi post a chi servono? :-)

Ti auguro un gain a tre zeri......intanto però senti il panico avvicinarsi e
non puoi fare niente... ;-)

CTIC (sospese in attesa di comunicato....)

> Ti auguro un gain a tre zeri......intanto però senti il panico avvicinarsi e
> non puoi fare niente... ;-)

BWAHAHAHAAHAHAHAHAHAA

> Questi post a chi servono? :-)
>
> Ti auguro un gain a tre zeri......intanto però senti il panico avvicinarsi
e
> non puoi fare niente... ;-)
>
> CTIC (sospese in attesa di comunicato....)
>


panico da preapertura americana?
non sembrerebbe panico

> esattto, mentre se dovesse partire a salire sul treno ci si mette 2
> secondi...
> mediate, mediate e poi mediate ancora....che diventerete
> ricchi...soprattutto da 8 euro.. :-(

....sei forte ely :-)

"l'orsotoro®" <lami@com.it> ha scritto nel messaggio
news:4371fc03$0$16212$4fafbaef@reader3.news.tin.it ...
>
> "@ SYBER_GURU @" <xxxi@virgilio.it> ha scritto nel messaggio
> news:4371fb40$0$27598$4fafbaef@reader1.news.tin.it ...
> > ORA TUTT IN GINOCCHIO AHAHHA chi era dentro guadagna come un maiale chi
e
> > fuori guarda SGRAT SGRAT
>
>
>
> Questi post a chi servono? :-)
>
> Ti auguro un gain a tre zeri......intanto però senti il panico avvicinarsi
e
> non puoi fare niente... ;-)

ALTRO CHE PANICO AHAHA QUESTA E NA MINIERA D'ORA PIXADONE ALTRO CHE XYROTAX
EUFORIAAAAAAAAAAAAAAAAAAAAAAAAA

"l'orsotoro®"
> Ti auguro un gain a tre zeri......intanto però senti il panico avvicinarsi
> e
> non puoi fare niente... ;-)
>
esattto, mentre se dovesse partire a salire sul treno ci si mette 2
secondi...
mediate, mediate e poi mediate ancora....che diventerete
ricchi...soprattutto da 8 euro.. :-(

> vedremo ahaha pero mi giuri che percorri in ginocchio piazza del duomo
sui
> ceci ;o) se tornera a 8 ahahah

devi specificare ...entro quando...tornera' a 8
perche' altrimenti ...oltre a farla sui ceci...mi metto a correre nudo
attorno alla piazza...hehehe

NEW YORK, Nov. 9 /PRNewswire-FirstCall/ -- At a presentation at the CIBC
World Markets 16th Annual Healthcare Conference, Cell Therapeutics, Inc.
(CTI)
(Nasdaq: CTIC; MTAX) presented results from a randomized controlled study of
Rituxan versus Rituxan plus pixantrone in 38 relapsed or refractory patients
who had previously failed up to five prior treatments for indolent
non-Hodgkin's lymphoma (NHL). The study achieved its primary objective of
prolonging the time before a patient's lymphoma progressed (time to disease
progression, or TTP). Patients receiving the combination of Rituxan and
pixantrone had an 87 percent overall improvement in TTP compared to Rituxan
alone. The median TTP estimate for the pixantrone/Rituxan recipients was
13.2 months compared to 8.1 months for Rituxan alone (hazard ratio 0.13, log
rank p <0.001). The one- and two-year progression-free survival estimates
were
66 percent and 44 percent for the pixantrone/Rituxan recipients compared to
zero percent for the Rituxan patients for both measurement intervals (p
<0.001
and 0.003, respectively). The study also met its secondary endpoint
demonstrating a significant improvement in major objective responses
(>/= 50 percent shrinkage in tumor size). Seventy-five percent of patients
treated with the pixantrone/Rituxan combination achieved a major response,
with 35 percent achieving a complete response. This compares to 33 percent
major response in patients who received Rituxan monotherapy, including 11
percent achieving a complete response (p = 0.02). Side effects on pixantrone
were generally mild (grade 1 or 2) with the exception of severe (grade 4)
treatment-related neutropenia, which was seen in two patients. The median
cumulative dose of pixantrone administered was 1014 mg/m2; no cases of
treatment-related grade 3 or 4 cardiac toxicity were reported.
"Obviously we are very pleased and excited by these results, which
demonstrate a significant advantage of adding pixantrone to the standard of
care, Rituxan, in treating indolent non-Hodgkin's lymphoma," noted Jack W.
Singer, M.D. Chief Medical Officer at CTI. "Despite the small sample size,
the
high degree of statistical significance underscores the notable activity of
pixantrone in indolent NHL."
About the Phase III trial
The multi-center randomized trial, also known as PIX302, evaluated the
addition of pixantrone (90 mg/m2 given on days 1 and 8 every 21 days) to
standard Rituxan therapy (375 mg/m2 given on days 1, 8, 22, and 29) to
Rituxan
therapy alone among patients with relapsed or refractory indolent NHL. The
trial was designed, pursuant to a SPA (Special Protocol Assessment) with the
FDA, to enroll a total of 728 patients in order to detect a 30 percent
improvement in TTP between treatment arms, the primary endpoint of the
study.
Overall response rate was a secondary endpoint of the trial. Patients with
histologically confirmed CD20 positive NHL who had failed one or more prior
treatments were included in the trial. Exclusion criteria consisted of
patients who were shown to be resistant to Rituxan or who had prior stem
cell
or bone marrow transplants. The study was stratified for known risk factors
that may impact response and duration of response including IPI
classification, number of prior regimens (1-2 versus >2), and prior
anti-CD20
regimen. Patients were followed for 24 months with disease assessments made
at
3-month intervals following their last day of drug therapy.
The study was closed in 2004 due to difficulty in meeting the initial
enrollment target. A total of 38 patients were evaluable for response; 20
patients (median age 67 years) were randomized to the pixantrone/Rituxan arm
with 18 patients (median age 59 years) on the Rituxan arm. The
pixantrone-Rituxan combination produced a complete response (CR) in seven
patients (35 percent), with 8 patients (40 percent) experiencing a partial
response (PR) and four patients (20 percent) with stable disease (SD).
Rituxan
monotherapy produced a CR in 2 patients (11 percent), PR in 4 patients (22
percent) with 6 patients having SD (33 percent). This corresponds to a major
objective response rate of 75 percent in the combination therapy arm
compared
to 33 percent in the Rituxan group (p=0.021). The combination of Rituxan and
pixantrone was well tolerated with the only severe (grade 4) toxicity
reported
being neutropenia in two patients. Other toxicities were generally mild to
moderate and consistent with the known safety profile for Rituxan
monotherapy,
except for mild (grade 1-2) cardiac side effects, fatigue, anorexia, and
alopecia, which were seen only on the combination treatment arm.

Sospeso un dual listing........a marzo no........che paese di merda!!!! la
consob serve a che cosa?

Sospeso un dual listing........a marzo no........che paese di merda!!!! la
consob serve a che cosa?

Sospeso un dual listing........a marzo no........che paese di merda!!!! la
consob serve a che cosa?

Sospeso un dual listing........a marzo no........che paese di merda!!!! la
consob serve a che cosa?

" ely" <ely2004xxx@alice.it> ha scritto nel messaggio
news:4371fce5$0$13253$4fafbaef@reader2.news.tin.it ...
>
> "l'orsotoro®"
> > Ti auguro un gain a tre zeri......intanto però senti il panico
avvicinarsi
> > e
> > non puoi fare niente... ;-)
> >
> esattto, mentre se dovesse partire a salire sul treno ci si mette 2
> secondi...
> mediate, mediate e poi mediate ancora....che diventerete
> ricchi...soprattutto da 8 euro.. :-(

vedremo ahaha pero mi giuri che percorri in ginocchio piazza del duomo sui
ceci ;o) se tornera a 8 ahahah

"@ SYBER_GURU @"

> vedremo ahaha pero mi giuri che percorri in ginocchio piazza del duomo sui
> ceci ;o) se tornera a 8 ahahah
>
te lo auguro, cosi' spero che a 8 almeno venderai e sarai in pari.....

"mascheroni ®" <mascheroni@guess.it> ha scritto nel messaggio
news:4371fde1$0$13254$4fafbaef@reader2.news.tin.it ...
> NEW YORK, Nov. 9 /PRNewswire-FirstCall/ -- At a presentation at the CIBC
> World Markets 16th Annual Healthcare Conference, Cell Therapeutics, Inc.
> (CTI)
> (Nasdaq: CTIC; MTAX) presented results from a randomized controlled study
of
> Rituxan versus Rituxan plus pixantrone in 38 relapsed or refractory
patients
> who had previously failed up to five prior treatments for indolent
> non-Hodgkin's lymphoma (NHL). The study achieved its primary objective of
> prolonging the time before a patient's lymphoma progressed (time to
disease
> progression, or TTP). Patients receiving the combination of Rituxan and
> pixantrone had an 87 percent overall improvement in TTP compared to
Rituxan
> alone. The median TTP estimate for the pixantrone/Rituxan recipients was
> 13.2 months compared to 8.1 months for Rituxan alone (hazard ratio 0.13,
log
> rank p <0.001). The one- and two-year progression-free survival estimates
> were
> 66 percent and 44 percent for the pixantrone/Rituxan recipients compared
to
> zero percent for the Rituxan patients for both measurement intervals (p
> <0.001
> and 0.003, respectively). The study also met its secondary endpoint
> demonstrating a significant improvement in major objective responses
> (>/= 50 percent shrinkage in tumor size). Seventy-five percent of patients
> treated with the pixantrone/Rituxan combination achieved a major response,
> with 35 percent achieving a complete response. This compares to 33 percent
> major response in patients who received Rituxan monotherapy, including 11
> percent achieving a complete response (p = 0.02). Side effects on
pixantrone
> were generally mild (grade 1 or 2) with the exception of severe (grade 4)
> treatment-related neutropenia, which was seen in two patients. The median
> cumulative dose of pixantrone administered was 1014 mg/m2; no cases of
> treatment-related grade 3 or 4 cardiac toxicity were reported.
> "Obviously we are very pleased and excited by these results, which
> demonstrate a significant advantage of adding pixantrone to the standard
of
> care, Rituxan, in treating indolent non-Hodgkin's lymphoma," noted Jack W.
> Singer, M.D. Chief Medical Officer at CTI. "Despite the small sample size,
> the
> high degree of statistical significance underscores the notable activity
of
> pixantrone in indolent NHL."
> About the Phase III trial
> The multi-center randomized trial, also known as PIX302, evaluated the
> addition of pixantrone (90 mg/m2 given on days 1 and 8 every 21 days) to
> standard Rituxan therapy (375 mg/m2 given on days 1, 8, 22, and 29) to
> Rituxan
> therapy alone among patients with relapsed or refractory indolent NHL. The
> trial was designed, pursuant to a SPA (Special Protocol Assessment) with
the
> FDA, to enroll a total of 728 patients in order to detect a 30 percent
> improvement in TTP between treatment arms, the primary endpoint of the
> study.
> Overall response rate was a secondary endpoint of the trial. Patients with
> histologically confirmed CD20 positive NHL who had failed one or more
prior
> treatments were included in the trial. Exclusion criteria consisted of
> patients who were shown to be resistant to Rituxan or who had prior stem
> cell
> or bone marrow transplants. The study was stratified for known risk
factors
> that may impact response and duration of response including IPI
> classification, number of prior regimens (1-2 versus >2), and prior
> anti-CD20
> regimen. Patients were followed for 24 months with disease assessments
made
> at
> 3-month intervals following their last day of drug therapy.
> The study was closed in 2004 due to difficulty in meeting the initial
> enrollment target. A total of 38 patients were evaluable for response; 20
> patients (median age 67 years) were randomized to the pixantrone/Rituxan
arm
> with 18 patients (median age 59 years) on the Rituxan arm. The
> pixantrone-Rituxan combination produced a complete response (CR) in seven
> patients (35 percent), with 8 patients (40 percent) experiencing a partial
> response (PR) and four patients (20 percent) with stable disease (SD).
> Rituxan
> monotherapy produced a CR in 2 patients (11 percent), PR in 4 patients (22
> percent) with 6 patients having SD (33 percent). This corresponds to a
major
> objective response rate of 75 percent in the combination therapy arm
> compared
> to 33 percent in the Rituxan group (p=0.021). The combination of Rituxan
and
> pixantrone was well tolerated with the only severe (grade 4) toxicity
> reported
> being neutropenia in two patients. Other toxicities were generally mild to
> moderate and consistent with the known safety profile for Rituxan
> monotherapy,
> except for mild (grade 1-2) cardiac side effects, fatigue, anorexia, and
> alopecia, which were seen only on the combination treatment arm.

inutile non ci capisce niente lei ha in mente 8 euro solo quello sa dire
STRA ROTFL AHAHAHHA

>
> panico da preapertura americana?
> non sembrerebbe panico
>
>

*** niente paura.... mio fratello ne ha una carrettata
*** piena zeppa..... e lui ha (_!_)
*** Trasforma la merda in cioccolata......
*** Se quel cazzone me lo avesse detto prima, sicuramente sarei entrato pure
io... ma non perchè lo si dice qui in ieb, ma perchè le ha lui :-(((

Che vuol dire?
Si sale o si scende?

mascheroni ® wrote:
> NEW YORK, Nov. 9 /PRNewswire-FirstCall/ -- At a presentation at the
> CIBC World Markets 16th Annual Healthcare Conference, Cell
> Therapeutics, Inc. (CTI)
> (Nasdaq: CTIC; MTAX) presented results from a randomized controlled
> study of Rituxan versus Rituxan plus pixantrone in 38 relapsed or
> refractory patients who had previously failed up to five prior
> treatments for indolent non-Hodgkin's lymphoma (NHL). The study
> achieved its primary objective of prolonging the time before a
> patient's lymphoma progressed (time to disease progression, or TTP).
> Patients receiving the combination of Rituxan and pixantrone had an
> 87 percent overall improvement in TTP compared to Rituxan alone. The
> median TTP estimate for the pixantrone/Rituxan recipients was
> 13.2 months compared to 8.1 months for Rituxan alone (hazard ratio
> 0.13, log rank p <0.001). The one- and two-year progression-free
> survival estimates were
> 66 percent and 44 percent for the pixantrone/Rituxan recipients
> compared to zero percent for the Rituxan patients for both
> measurement intervals (p <0.001
> and 0.003, respectively). The study also met its secondary endpoint
> demonstrating a significant improvement in major objective responses
> (>/= 50 percent shrinkage in tumor size). Seventy-five percent of
> patients treated with the pixantrone/Rituxan combination achieved a
> major response, with 35 percent achieving a complete response. This
> compares to 33 percent major response in patients who received
> Rituxan monotherapy, including 11 percent achieving a complete
> response (p = 0.02). Side effects on pixantrone were generally mild
> (grade 1 or 2) with the exception of severe (grade 4)
> treatment-related neutropenia, which was seen in two patients. The
> median cumulative dose of pixantrone administered was 1014 mg/m2; no
> cases of treatment-related grade 3 or 4 cardiac toxicity were
> reported. "Obviously we are very pleased and excited by these
> results, which demonstrate a significant advantage of adding
> pixantrone to the standard of care, Rituxan, in treating indolent
> non-Hodgkin's lymphoma," noted Jack W. Singer, M.D. Chief Medical
> Officer at CTI. "Despite the small sample size, the
> high degree of statistical significance underscores the notable
> activity of pixantrone in indolent NHL."
> About the Phase III trial
> The multi-center randomized trial, also known as PIX302, evaluated the
> addition of pixantrone (90 mg/m2 given on days 1 and 8 every 21 days)
> to standard Rituxan therapy (375 mg/m2 given on days 1, 8, 22, and
> 29) to Rituxan
> therapy alone among patients with relapsed or refractory indolent
> NHL. The trial was designed, pursuant to a SPA (Special Protocol
> Assessment) with the FDA, to enroll a total of 728 patients in order
> to detect a 30 percent improvement in TTP between treatment arms, the
> primary endpoint of the study.
> Overall response rate was a secondary endpoint of the trial. Patients
> with histologically confirmed CD20 positive NHL who had failed one or
> more prior treatments were included in the trial. Exclusion criteria
> consisted of patients who were shown to be resistant to Rituxan or
> who had prior stem cell
> or bone marrow transplants. The study was stratified for known risk
> factors that may impact response and duration of response including
> IPI classification, number of prior regimens (1-2 versus >2), and
> prior anti-CD20
> regimen. Patients were followed for 24 months with disease
> assessments made at
> 3-month intervals following their last day of drug therapy.
> The study was closed in 2004 due to difficulty in meeting the initial
> enrollment target. A total of 38 patients were evaluable for
> response; 20 patients (median age 67 years) were randomized to the
> pixantrone/Rituxan arm with 18 patients (median age 59 years) on the
> Rituxan arm. The pixantrone-Rituxan combination produced a complete
> response (CR) in seven patients (35 percent), with 8 patients (40
> percent) experiencing a partial response (PR) and four patients (20
> percent) with stable disease (SD). Rituxan
> monotherapy produced a CR in 2 patients (11 percent), PR in 4
> patients (22 percent) with 6 patients having SD (33 percent). This
> corresponds to a major objective response rate of 75 percent in the
> combination therapy arm compared
> to 33 percent in the Rituxan group (p=0.021). The combination of
> Rituxan and pixantrone was well tolerated with the only severe (grade
> 4) toxicity reported
> being neutropenia in two patients. Other toxicities were generally
> mild to moderate and consistent with the known safety profile for
> Rituxan monotherapy,
> except for mild (grade 1-2) cardiac side effects, fatigue, anorexia,
> and alopecia, which were seen only on the combination treatment arm.

Che vuol dire?
Si sale o si scende?

mascheroni ® wrote:
> NEW YORK, Nov. 9 /PRNewswire-FirstCall/ -- At a presentation at the
> CIBC World Markets 16th Annual Healthcare Conference, Cell
> Therapeutics, Inc. (CTI)
> (Nasdaq: CTIC; MTAX) presented results from a randomized controlled
> study of Rituxan versus Rituxan plus pixantrone in 38 relapsed or
> refractory patients who had previously failed up to five prior
> treatments for indolent non-Hodgkin's lymphoma (NHL). The study
> achieved its primary objective of prolonging the time before a
> patient's lymphoma progressed (time to disease progression, or TTP).
> Patients receiving the combination of Rituxan and pixantrone had an
> 87 percent overall improvement in TTP compared to Rituxan alone. The
> median TTP estimate for the pixantrone/Rituxan recipients was
> 13.2 months compared to 8.1 months for Rituxan alone (hazard ratio
> 0.13, log rank p <0.001). The one- and two-year progression-free
> survival estimates were
> 66 percent and 44 percent for the pixantrone/Rituxan recipients
> compared to zero percent for the Rituxan patients for both
> measurement intervals (p <0.001
> and 0.003, respectively). The study also met its secondary endpoint
> demonstrating a significant improvement in major objective responses
> (>/= 50 percent shrinkage in tumor size). Seventy-five percent of
> patients treated with the pixantrone/Rituxan combination achieved a
> major response, with 35 percent achieving a complete response. This
> compares to 33 percent major response in patients who received
> Rituxan monotherapy, including 11 percent achieving a complete
> response (p = 0.02). Side effects on pixantrone were generally mild
> (grade 1 or 2) with the exception of severe (grade 4)
> treatment-related neutropenia, which was seen in two patients. The
> median cumulative dose of pixantrone administered was 1014 mg/m2; no
> cases of treatment-related grade 3 or 4 cardiac toxicity were
> reported. "Obviously we are very pleased and excited by these
> results, which demonstrate a significant advantage of adding
> pixantrone to the standard of care, Rituxan, in treating indolent
> non-Hodgkin's lymphoma," noted Jack W. Singer, M.D. Chief Medical
> Officer at CTI. "Despite the small sample size, the
> high degree of statistical significance underscores the notable
> activity of pixantrone in indolent NHL."
> About the Phase III trial
> The multi-center randomized trial, also known as PIX302, evaluated the
> addition of pixantrone (90 mg/m2 given on days 1 and 8 every 21 days)
> to standard Rituxan therapy (375 mg/m2 given on days 1, 8, 22, and
> 29) to Rituxan
> therapy alone among patients with relapsed or refractory indolent
> NHL. The trial was designed, pursuant to a SPA (Special Protocol
> Assessment) with the FDA, to enroll a total of 728 patients in order
> to detect a 30 percent improvement in TTP between treatment arms, the
> primary endpoint of the study.
> Overall response rate was a secondary endpoint of the trial. Patients
> with histologically confirmed CD20 positive NHL who had failed one or
> more prior treatments were included in the trial. Exclusion criteria
> consisted of patients who were shown to be resistant to Rituxan or
> who had prior stem cell
> or bone marrow transplants. The study was stratified for known risk
> factors that may impact response and duration of response including
> IPI classification, number of prior regimens (1-2 versus >2), and
> prior anti-CD20
> regimen. Patients were followed for 24 months with disease
> assessments made at
> 3-month intervals following their last day of drug therapy.
> The study was closed in 2004 due to difficulty in meeting the initial
> enrollment target. A total of 38 patients were evaluable for
> response; 20 patients (median age 67 years) were randomized to the
> pixantrone/Rituxan arm with 18 patients (median age 59 years) on the
> Rituxan arm. The pixantrone-Rituxan combination produced a complete
> response (CR) in seven patients (35 percent), with 8 patients (40
> percent) experiencing a partial response (PR) and four patients (20
> percent) with stable disease (SD). Rituxan
> monotherapy produced a CR in 2 patients (11 percent), PR in 4
> patients (22 percent) with 6 patients having SD (33 percent). This
> corresponds to a major objective response rate of 75 percent in the
> combination therapy arm compared
> to 33 percent in the Rituxan group (p=0.021). The combination of
> Rituxan and pixantrone was well tolerated with the only severe (grade
> 4) toxicity reported
> being neutropenia in two patients. Other toxicities were generally
> mild to moderate and consistent with the known safety profile for
> Rituxan monotherapy,
> except for mild (grade 1-2) cardiac side effects, fatigue, anorexia,
> and alopecia, which were seen only on the combination treatment arm.

" ely" <ely2004xxx@alice.it> ha scritto nel messaggio
news:4371fe85$0$13264$4fafbaef@reader2.news.tin.it ...
>
> "@ SYBER_GURU @"
>
> > vedremo ahaha pero mi giuri che percorri in ginocchio piazza del duomo
sui
> > ceci ;o) se tornera a 8 ahahah
> >
> te lo auguro, cosi' spero che a 8 almeno venderai e sarai in pari.....


vendere alla pari sei come i comunisti hanno il apraocchi e sparano cazzate
a non finire vai a nasconderti

"ghost" <ghost66@libero.it> ha scritto nel messaggio
news:dksuqv$g20$1@area.cu.mi.it...
> > vedremo ahaha pero mi giuri che percorri in ginocchio piazza del duomo
> sui
> > ceci ;o) se tornera a 8 ahahah
>
> devi specificare ...entro quando...tornera' a 8
> perche' altrimenti ...oltre a farla sui ceci...mi metto a correre nudo
> attorno alla piazza...hehehe

non sarei GURU ma un mago!!

"Gaetano" <gaetanofh@fastwebnet.it> ha scritto nel messaggio
news:v8ncf.9910$OR3.6877@tornado.fastwebnet.it...
> Che vuol dire?
> Si sale o si scende?

ti traduco solo una parte

"Obviously we are very pleased and excited by these results, which
demonstrate a significant advantage of adding pixantrone to the standard of
care, Rituxan, in treating indolent non-Hodgkin's lymphoma

Ovvio il nostro grande piacere ed eccitazione per questi risultati, che
dimostrano
un vantaggio significativo nell'aggiungere pixantrone alla cura
tradizionale, Rituxa,
nel trattamento dell "indolent non-Hodgkin's lymphoma"

> io comunista?
>
> rotfl

ti pensavo... con i tacchi a spillo.. ma non comunista ... :-)))

"@ SYBER_GURU @" <xxxi@virgilio.it> ha scritto nel messaggio
>

> vendere alla pari sei come i comunisti hanno il apraocchi e sparano
> cazzate
> a non finire vai a nasconderti
>
io comunista?

rotfl

> io comunista?
>
> rotfl

ahahahhahahahahahahahhahahaha

si son testimone va alle manifestazioni del 1 maggio con Will


ahahahahhahahahahahhahahahaha

" .®" <aaa@xx.com> ha scritto nel messaggio
news:3tedp6Fs8q6cU1@individual.net...
>
>> io comunista?
>>
>> rotfl
>
> ahahahhahahahahahahahhahahaha
>
> si son testimone va alle manifestazioni del 1 maggio con Will
>
>
> ahahahahhahahahahahhahahahaha
AHAHAAAAHAHAHHAAHAAHAAH

> ti pensavo... con i tacchi a spillo.. ma non comunista ... :-)))
>
>

è una militante di shorta continua

Avanti popolo...
alla riscossa.........


" .®" <aaa@xx.com> ha scritto nel messaggio
news:3tedp6Fs8q6cU1@individual.net...
>
>> io comunista?
>>
>> rotfl
>
> ahahahhahahahahahahahhahahaha
>
> si son testimone va alle manifestazioni del 1 maggio con Will
>
>
> ahahahahhahahahahahhahahahaha
>

"Esorcist@" <è.Mattanz@.alè!!!> ha scritto nel messaggio
news:437201bb$0$13260$4fafbaef@reader2.news.tin.it ...
> Avanti popolo...
> alla riscossa.........


agli esorcisti rompiam le ossa

Azzzzzzzzzz!!!!!!

No...
Nooooo
Noooooooo...

Non mi sembra fosse così??????


" .®" <aaa@xx.com> ha scritto nel messaggio
news:3tee1lFsa4h4U1@individual.net...
>
> "Esorcist@" <è.Mattanz@.alè!!!> ha scritto nel messaggio
> news:437201bb$0$13260$4fafbaef@reader2.news.tin.it ...
>> Avanti popolo...
>> alla riscossa.........
>
>
> agli esorcisti rompiam le ossa
>

> panico da preapertura americana?
> non sembrerebbe panico


Nel pre usa siamo a 2.80$ con un high a 2.93$......

Non sembra panico......ma allora perchè l'hanno sospesa in Italia?

Non capisco come si possa lavorare su un titolo del genere.........

Sono scommesse.....allo stesso modo dei 5 numeri del lotto......gioco
1-2-3-4-5 e poi spero che escano....

I titoli seri sono quelli che mi permettono di impostare una
strategia...coperture...arbitraggi....

Con cell se scommetti (meglio non usare il termine "operi") al rialzo....ne
compri un po'....poi ti prendi un caffè...aspetti che le riammettano....se è
andata bene fai un gain mostruso...se è andata male.....medi... ;-)))

>> panico da preapertura americana?
>> non sembrerebbe panico
>
>
> Nel pre usa siamo a 2.80$ con un high a 2.93$......
>
> Non sembra panico......ma allora perchè l'hanno sospesa in Italia?
>
> Non capisco come si possa lavorare su un titolo del genere.........
>
> Sono scommesse.....allo stesso modo dei 5 numeri del lotto......gioco
> 1-2-3-4-5 e poi spero che escano....
>
> I titoli seri sono quelli che mi permettono di impostare una
> strategia...coperture...arbitraggi....
>
> Con cell se scommetti (meglio non usare il termine "operi") al
> rialzo....ne
> compri un po'....poi ti prendi un caffè...aspetti che le riammettano....se
> è
> andata bene fai un gain mostruso...se è andata male.....medi... ;-)))
>
>
Qui la responsabilità è tutta di chi dirige borsa italiana e della consob
che come sempre non c'è o arriva a giochi strafatti. L'hanno sospesa senza
ragione e contro le regole previste nei titoli dual listing, oltretutto già
scambiava nel pre- usa e lì non ci sono sospensioni per rialzo o ribasso.
Una vera vergogna che qualifica a chi stiamo in mano

>> panico da preapertura americana?
>> non sembrerebbe panico
>
>
> Nel pre usa siamo a 2.80$ con un high a 2.93$......
>
> Non sembra panico......ma allora perchè l'hanno sospesa in Italia?
>
> Non capisco come si possa lavorare su un titolo del genere.........
>
> Sono scommesse.....allo stesso modo dei 5 numeri del lotto......gioco
> 1-2-3-4-5 e poi spero che escano....
>
> I titoli seri sono quelli che mi permettono di impostare una
> strategia...coperture...arbitraggi....
>
> Con cell se scommetti (meglio non usare il termine "operi") al
> rialzo....ne
> compri un po'....poi ti prendi un caffè...aspetti che le riammettano....se
> è
> andata bene fai un gain mostruso...se è andata male.....medi... ;-)))
>
>
Qui la responsabilità è tutta di chi dirige borsa italiana e della consob
che come sempre non c'è o arriva a giochi strafatti. L'hanno sospesa senza
ragione e contro le regole previste nei titoli dual listing, oltretutto già
scambiava nel pre- usa e lì non ci sono sospensioni per rialzo o ribasso.
Una vera vergogna che qualifica a chi stiamo in mano

>> panico da preapertura americana?
>> non sembrerebbe panico
>
>
> Nel pre usa siamo a 2.80$ con un high a 2.93$......
>
> Non sembra panico......ma allora perchè l'hanno sospesa in Italia?
>
> Non capisco come si possa lavorare su un titolo del genere.........
>
> Sono scommesse.....allo stesso modo dei 5 numeri del lotto......gioco
> 1-2-3-4-5 e poi spero che escano....
>
> I titoli seri sono quelli che mi permettono di impostare una
> strategia...coperture...arbitraggi....
>
> Con cell se scommetti (meglio non usare il termine "operi") al
> rialzo....ne
> compri un po'....poi ti prendi un caffè...aspetti che le riammettano....se
> è
> andata bene fai un gain mostruso...se è andata male.....medi... ;-)))
>
>
Qui la responsabilità è tutta di chi dirige borsa italiana e della consob
che come sempre non c'è o arriva a giochi strafatti. L'hanno sospesa senza
ragione e contro le regole previste nei titoli dual listing, oltretutto già
scambiava nel pre- usa e lì non ci sono sospensioni per rialzo o ribasso.
Una vera vergogna che qualifica a chi stiamo in mano